Roger Perlmutter, M.D. Ph.D. Chairman of the Board Executive Vice President, Research and Development Amgen, Inc.
Bill Bowes Co-Founder U. S. Venture Partners	Thomas J. Cable Board Member Omeros Corporation
Chuck Hirsch Founding Partner MHz, LLC.	Leroy Hood, M.D. Ph.D. President Institute for Systems Biology
Louis G. Lange, M.D., Ph.D. Senior Adviser Gilead	Garry Menzel, Ph.D. Executive Vice President, Corporate Development and Finance Regulus Therapeutics
George Rathmann, Ph.D. Director Emeritus Chairman Nuvelo, Inc.	David A. Sabey President Sabey Corporation & Sabey Construction

Board of Directors Biographies:

Bill Bowes, a co-founder of U.S. Venture Partners, has been an active and prominent venture capital investor in the San Francisco Bay Area for nearly 40 years. Prior to founding USVP, Mr. Bowes had already established himself as a leading venture capitalist in the Bay Area with such major successes as Amgen, where he was the founding shareholder (and its first employee, Chairman and Treasurer), Cetus (where Bowes served as a director), Raychem (where he also served on the Board from 1961 until the late 1970's), and Dymo, among others.

At USVP, which he co-founded in 1981, Mr. Bowes sourced and led the Firm's investments in Advanced Cardiovascular Systems, Applied Biosystems, Devices for Vascular Intervention, Glycomed and Ventritex, among numerous others. Since its founding, USVP has invested more than $1.8 billion in more than 350 companies. Bowes currently serves on the Board of Directors of Xoma, a leading biopharmaceutical company in the field of therapeutic antibody discovery and development.

Before founding USVP, Mr. Bowes was a Senior Vice President and Director of Blyth Eastman Dillon & Co. (formerly Blyth & Co. Inc.), where he worked from 1953 until 1978, and was a consultant to Blyth Eastman Paine Webber from 1978 to 1980. Bowes has a B.A. in Economics from Stanford and an M.B.A. from Harvard Business School.

Bowes serves as vice-chair of the board of directors for the San Francisco Conservatory of Music, is a trustee on the board of directors for the Asian Art Museum in San Francisco, and is a trustee of the Hoover Institution. He serves on the advisory committee of the Bio-X Initiative, an effort by Stanford University to foster interdisciplinary medical research. He recently stepped down as chairman of the San Francisco Exploratorium, an interactive museum of science. Mr. Bowes also served very successfully as Chairman of the Mission Bay Campaign, a $240 million initiative of the University of California San Francisco. Back to top



Thomas J. Cable has played leading roles in finance and investment firms for much of his distinguished career. He was partner in Cable, Howse & Ragen, investment bankers (now known as Ragen Mackenzie, a division of Wells Fargo) and co-founder of Cable & Howse Ventures. With the latter firm, Mr. Cable was a founding investor in Immunex and Zymogenetics and served on those corporations' boards of directors.

He is currently chairman of the Washington Research Foundation (WRF), which he co-founded in 1981. WRF assists universities and other nonprofit research institutions in the state of Washington with commercialization of their technologies and provides support, through gifts and grants, for their scholarship and research. Mr. Cable also serves on the board of Omeros Corporation, as chairman of the advisory board of the Applied Physics Laboratory and as a member of the advancement board of Friday Harbor Laboratories.

He is past chairman of the University of Washington President's Club, co-founder and vice chairman of the Technology Alliance and a founder of the Alliance of Angels, organizations dedicated to successful technology development by Northwest-based entrepreneurs. Mr. Cable is a former U.S. Navy submarine officer, and received his M.B.A. from the Stanford Graduate School of Business and his B.A. from Harvard University.

Back to top

Chuck Hirsch is a Founding Partner of MHz, LLC, a strategic advisory firm focused on U.S.-China privatization opportunities. He served for seven years as a Managing Director of Madrona Venture Group.

Prior to this he co-founded Dare to Dream Intertainment, which was acquired by Microsoft Corporation. Dare to Dream pioneered the use of wireless technology in the home entertainment market. As an executive at Microsoft he co-led the development and launch of Microsoft's Actimates® product line, which revolutionized the interactive toy and early learning markets.

He served as Executive Vice President of the Amelior Foundation in New Jersey, where he helped to create the New Jersey Performing Arts Center in Newark, the national Points of Light Foundation, the One to One National Mentoring Partnership and the global Heal the World Foundation. Prior to this he served as Chief of Staff of the Port Authority of New York and New Jersey. He is a former White House Fellow where he served as a Special Assistant in the offices of the U.S. Secretaries of Defense and the Navy.

In addition to serving as a Director of ISB, he serves as President of the board of the Microsoft Alumni Foundation, was a long-standing member of the Board of Trustees of the Fred Hutchinson Cancer Research Center and the White House Fellows Association, and was instrumental in the creation of Washington State's Life Sciences Discovery Fund. Mr. Hirsch is a graduate of Williams College.

Back to top



Louis G. Lange, M.D., Ph.D. Dr. Lange has 22 years experience in academic medicine at Harvard Medical School and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital from 1985-1992 and was one of the first academicians in molecular cardiology.

He founded CV Therapeutics based on this broad field and as Chairman, CEO and Chief Scientific Officer, led the IPO in 1996 and the overall pipeline development and the initiatives for US FDA and European EMEA approval for Ranexa®, a first-in-class late sodium channel blocker and the first anti-anginal drug class approved in 30 years in the US. He also led the approval of Lexiscan®, a first-in-class adenosine A2a receptor agonist for use in myocardial perfusion imaging studies. Dr. Lange oversaw the commercial success of CV Therapeutics and its sale to Gilead in 2009 for $1.4 billion dollars.

As a member of the Board of Trustees at the University of Rochester since 1998 and as Chair of the Health Affairs committee that oversees all of the medical operations for five years, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center with construction of two research buildings and recruitment of over 100 faculty members. As a member of BIO Board of Directors (the trade organization of biotech companies) from 1999 to 2009, Dr. Lange led the largest committee of member companies for two years and was picked as one of two biotech executives to attend the ceremonies at the White House for the signing of the Bioterrorism bill in 2004. Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena.

Back to top

Dr. Garry Menzel is Executive Vice President, Corporate Development & Finance for Regulus Therapeutics, a biotechnology company that specializes in microRNA research. Before joining Regulus in August of 2008, Dr. Garry Menzel was a Managing Director and Global Head of Life Sciences for Credit Suisse. He joined Credit Suisse in 2004, serving a broad range of biotechnology and pharmaceutical clients around the world, raising capital and negotiating merger agreements. Prior to joining Credit Suisse, he was a Managing Director and Global Head of Biotechnology for Goldman Sachs. Dr. Menzel joined Goldman Sachs in 1994 and was a founding member of the Healthcare Group. Prior to his career on Wall Street, Dr. Menzel was a strategy consultant for Bain & Company, working on a variety of operational projects in Europe and Asia. Dr. Menzel earned a B.Sc. with Honors in Biochemistry from the Imperial College of Science & Technology in London, England in 1985, a Ph.D. in Molecular Biology from the University of Cambridge in 1988, and an M.B.A. from the Stanford Graduate School of Business in 1994. He is an Associate of the Royal College of Science. Dr. Menzel is a member of the board of directors for the Institute for Systems Biology and the Epilepsy Therapy Project, where he chairs the Business Advisory Committee.

Back to top

Dr. Roger Perlmutter is the Chairman of the Board at the Institute for Systems Biology.

Dr. Perlmutter joined Amgen as executive vice president, Research and Development in January 2001. Perlmutter oversees the company's worldwide research and development operations.

Before joining Amgen, Dr. Perlmutter was executive vice president at Merck Research Laboratories. He also held positions as chairman, Dept. of Immunology, at the University of Washington; and, from 1991 to 1997, was an investigator for Howard Hughes Medical Institute. Dr. Perlmutter received his bachelor's degree in 1973 from Reed College, Portland, Oregon, and his M.D. and Ph.D. from Washington University, St. Louis, Missouri in 1979.

Back to top

Dr. George Rathmann joined Nuvelo, Inc. (formerly Hyseq, Pharmaceuticals, Inc.) as Chairman, in February 2000. Prior to that, Dr. Rathmann was a founder of ICOS Corporation and served as Chairman of the Board from 1990 until January 2000. While at ICOS, he also served as Chief Executive Officer and President, from September 1991 until June 1999. Prior to ICOS, Dr. Rathmann co-founded Amgen, Inc. in 1980, where he served as a Director until 1993. At Amgen, Dr. Rathmann also served as Chairman of the Board, Chief Executive Officer and President at various times.

Before joining Amgen, Dr. Rathmann was Vice President, Research and Development, Diagnostics Division, of Abbott Laboratories, which he joined in 1975. Also during his professional career, Dr. Rathmann served as President of Litton Medical Systems, Inc. He previously held research and management positions at the 3M Company, over a period of twenty years.

Since 1982, he has served as an Officer and Board Member of the Biotechnology Industry Organization and was Chairman from 1986-1988. Dr. Rathmann is an Officer and Board Member of the National Science and Technology Medals Foundation. He is on the Board of Trustees of the Fred Hutchinson Cancer Research Center and the Keystone Center. Dr. Rathmann is the Chairman of the Board of Directors of Zymogentics Inc and Ceptyr, Inc.

Dr. Rathmann received his B.S. in Physical Chemistry from Northwestern University, and his Ph.D. in Physical Chemistry from Princeton University. He is a member of the National Academy of Engineering, the American Association for the Advancement of Science, and the American Chemical Society.

Dr. Rathmann was the recipient of The Glen T. Seaborg Medal from UCLA, 1995; The Bower Award for Business Leadership, 1997; the Biotechnology Heritage Award, Chemical Heritage Foundation and BIO, 1999; and the Princeton Madison Medal Award.

Back to top

David A. Sabey was born and raised in Washington State. Dave has spent the past 40 years building a successful real estate development company specializing in office and technology-driven industries including data centers and health care. Through that experience, he has developed a keen awareness of the importance of communications technology as a key driver of our economy and as a means to leverage the world's diverse intellectual capital by sharing its most sophisticated skill sets.

Accordingly, Dave recently established the Seattle Science Foundation to support the collaboration of medical science and technology through high bandwidth transmissions among the world's most talented practitioners. Through SSF and his involvement in the region's growing medical community, Dave is helping to advance a global healthcare network with Seattle as a central node.

Dave and his wife, Sandy, have three children, two of whom work in the family business.


Back to top